Premium
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia
Author(s) -
Pant Shubham,
Hamadani Mehdi,
Dodds Anthony J.,
Szer Jeffrey,
Crilley Pamela A.,
Stevenson Dustin,
Phillips Gary,
Elder Patrick,
NivisonSmith Ian,
Avalos Belinda R.,
Penza Sam,
Topolsky David,
Sobecks Ronald,
Kalaycio Matt,
Bolwell Brian J.,
Copelan Edward A.
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07947.x
Subject(s) - medicine , busulfan , cyclophosphamide , cumulative incidence , incidence (geometry) , transplantation , myeloid leukaemia , sibling , myeloid , disease , immunology , surgery , gastroenterology , chemotherapy , psychology , developmental psychology , physics , optics
Summary The long‐term follow‐up is presented for 317 patients with acute myeloid leukaemia who underwent human leucocyte antigen‐identical sibling marrow transplants between 1984 and 1995 following preparation with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. Among the 142 (45%) who were alive and leukaemia‐free 3 years following transplantation, the leukaemia‐free survival at 15 years was 72·8%. The cumulative incidence of late (>3 years beyond transplant) non‐relapse mortality at 15 years was 12·9% and of late relapse was 16·5%. None of the variables considered (including age, disease stage, and graft‐ versus ‐host disease) were predictive of late failure.